<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2393">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05545657</url>
  </required_header>
  <id_info>
    <org_study_id>2022-LCYJ-MS-03</org_study_id>
    <nct_id>NCT05545657</nct_id>
  </id_info>
  <brief_title>Relationship and Central Mechanism Between Diabetes and Cognitive Impairment Based on Simultaneous EEG-fMRI Approach and Peripheral Neuropathology Biomarkers Assay</brief_title>
  <official_title>A Cross-sectional and Longitudinal Study to Investigate the Relationship and Central Mechanism Between Diabetes and Cognitive Impairment Based on Simultaneous EEG-fMRI Approach and Peripheral Neuropathology Biomarkers Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cross-sectional and longitudinal study to investigate the relationship and central&#xD;
      mechanism between type 2 diabetes and cognitive impairment based on the simultaneous EEG-fMRI&#xD;
      approach and peripheral neuropathology biomarkers assay.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Little is known about the high risks of cognitive impairment and Alzheimer's Disease (AD) in&#xD;
      people with type 2 diabetes. The goal of this study is to characterize brain imaging&#xD;
      biomarkers of preclinical AD and related cognitive impairment in people with type 2 diabetes&#xD;
      using the simultaneous EEG-fMRI approach and peripheral neuropathology biomarkers assay. We&#xD;
      will recruit 400 patients with type 2 diabetes in the outpatient and inpatient departments.&#xD;
      Each subject will undergo simultaneous EEG-fMRI scan, classical multimodal MRI scan,&#xD;
      cognitive assessments and peripheral neuropathology biomarkers assay at the baseline. This&#xD;
      study will qualify gray matter volume, cortical thickness, gray matter and white matter&#xD;
      microstructure, cerebral blood flow, spectrum changes, as well as resting state and dynamic&#xD;
      functional network connectivity from the imaging examination. Study duration was 3 years with&#xD;
      a follow-up every 12 months. Cognitive assessments and imaging scan will be conducted in each&#xD;
      follow-up visits. At the end of the study, all of the assessments will be performed again for&#xD;
      all recruited subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 18, 2022</start_date>
  <completion_date type="Anticipated">August 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline cognitive performance</measure>
    <time_frame>Day 1 of entry study</time_frame>
    <description>The Montreal Cognitive Assessment (MoCA) score, ranges from 0 to 30, and higher scores mean better cognition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline peripheral blood neuropathology biomarkers level</measure>
    <time_frame>Blood samples will be collected on day 1 of the entry study and preserved at -81 °C in the Biobank of Drum Tower Hospital until examination.</time_frame>
    <description>Aβ40, Aβ42, P-tau 181, P-tau 231, GFAP and NfL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline simultaneous EEG-fMRI</measure>
    <time_frame>Within 1 week after cognitive assessments</time_frame>
    <description>Frequency domain and spectrum domain analyses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline brain structural MRI scan</measure>
    <time_frame>Within 1 week after cognitive assessments</time_frame>
    <description>Cortical morphology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline brain functional MRI scan</measure>
    <time_frame>Within 1 week after cognitive assessments</time_frame>
    <description>Large-scale network functional connectivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Longitudinal changes of cognitive performance</measure>
    <time_frame>From baseline to each follow-up time points (6 months, 12 months, 18 months, 24 months, 30months, 36 months).</time_frame>
    <description>Compare the change of MoCA score from baseline to each follow-up time points (6 months, 12 months, 18 months, 24 months, 30months, 36 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal changes of peripheral blood neuropathology biomarkers level</measure>
    <time_frame>From baseline to final follow-up time points (36 months).</time_frame>
    <description>Compare the changes of peripheral blood neuropathology biomarkers level from baseline to final follow-up time points (36 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal changes of simultaneous EEG-fMRI</measure>
    <time_frame>From baseline to each follow-up time points (6 months, 12 months, 18 months, 24 months, 30months, 36 months).</time_frame>
    <description>Compare the change of frequency domain and spectrum domain from baseline to each follow-up time points (6 months, 12 months, 18 months, 24 months, 30months, 36 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal changes of brain structural MRI scan</measure>
    <time_frame>From baseline to each follow-up time points (6 months, 12 months, 18 months, 24 months, 30months, 36 months).</time_frame>
    <description>Compare the changes of cortical morphology from baseline to each follow-up time points (6 months, 12 months, 18 months, 24 months, 30months, 36 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal changes of brain functional MRI scan</measure>
    <time_frame>From baseline to each follow-up time points (6 months, 12 months, 18 months, 24 months, 30months, 36 months).</time_frame>
    <description>Compare the changes of large-scale network functional connectivity from baseline to each follow-up time points (6 months, 12 months, 18 months, 24 months, 30months, 36 months).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
    <description>These patients must have a definite diagnosis of type 2 diabetes mellitus (T2DM) according to the American Diabetes Association (ADA) standards. Some of these patients have symptoms of cognitive impairment, while others have normal cognition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <description>These participants have normal glucose tolerance and normal cognition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive assessments</intervention_name>
    <description>Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Rey Auditory Verbal Learning Test (RAVLT), Boston Naming Test (BNT), Digit Span Test (DST), Trail Making Test (TMT).</description>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Simultaneous EEG-fMRI scan</intervention_name>
    <description>EEG recordings were conducted with a 64-channel MR-compatible EEG system (Electrical Geodesics Inc., Eugene, OR, USA) and an MR-compatible EEG cap (HydroCel Geodesic Sensor Nets), using ring-type sintered silver chloride electrodes with iron-free copper leads.</description>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multimodal magnetic resonance imaging</intervention_name>
    <description>3D T1-weighted imaging, Resting-state fMRI, Diffusion tensor imaging, Arterial spin labeling.</description>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Peripheral blood neuropathology biomarkers assay</intervention_name>
    <description>Detecting the peripheral blood neuropathology biomarkers using single molecule array (Simoa) technique, including Aβ40, Aβ42, P-tau 181, P-tau 231, GFAP and NfL.</description>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>Type 2 Diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        T2DM patients will be recruited from the outpatient and inpatient units of the&#xD;
        endocrinology department of the investigator's hospital. Healthy control will be recruited&#xD;
        in the community&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 40-75 years&#xD;
&#xD;
          -  Right handedness&#xD;
&#xD;
          -  Possessed over 6-year education&#xD;
&#xD;
          -  Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Control participants would be excluded if they had a fasting blood glucose level &gt;7.0&#xD;
             mmol/L; glucose level&gt; 7.8 mmol/L after oral glucose tolerance test (OGTT); HbA1c&gt;5.7%&#xD;
&#xD;
          -  Control participants would be excluded if they had a Montreal Cognitive Assessment&#xD;
             (MoCA, Beijing edition) score of &lt; 26&#xD;
&#xD;
          -  History of other dementia-related neurological or psychiatric disorders, including&#xD;
             psychotic developmental disorders, mania, depression, and schizophrenia&#xD;
&#xD;
          -  Central neural system diseases, including traumatic brain injury, intracranial&#xD;
             hemorrhage, and acute cerebral infarction&#xD;
&#xD;
          -  Acute complications of diabetes, including diabetic ketoacidosis, hyperglycemic&#xD;
             hyperosmolar state, and hypoglycemic coma&#xD;
&#xD;
          -  Complicated with severe impairment of liver, kidney or heart function&#xD;
&#xD;
          -  Metal implants, unable to complete the MR scanning&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bing Zhang, MD, PhD</last_name>
    <phone>86-15851803070</phone>
    <email>zhangbing_nanjing@vip.163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wen Zhang, MD, PhD</last_name>
    <phone>86-15950576908</phone>
    <email>zw7830254@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Radiology, the Affiliated Drum Tower Hospital of Nanjing University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bing Zhang, MD, PhD</last_name>
      <phone>86-15851803070</phone>
      <email>zhangbing_nanjing@vip.163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>September 6, 2022</study_first_submitted>
  <study_first_submitted_qc>September 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2022</study_first_posted>
  <last_update_submitted>October 23, 2022</last_update_submitted>
  <last_update_submitted_qc>October 23, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD sharing will be made during the 12 months after the end of study, and the original data can be obtained from the PI if necessary.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>during the 12 months after the end of study</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

